



Fig. S1. (a, b) Long-term partial remission of lymph nodes and amelioration of skin with resolution of infiltration and erythema while exhibiting incremental "nappes claires" 12 months after initiation of combination treatment with brentuximab vedotin and extracorporeal photopheresis (ECP). (c) Reduction in CD4/CD8 ratio and undulating lactate dehydrogenase (LDH) levels since initiation of monotherapy with brentuximab vedotin and after addition of ECP. *Green arrowheads*: Treatment cycles of brentuximab vedotin, 1.8 mg/m², every 3 (–4) weeks. *Red arrowheads*: Additional treatment with ECP on two consecutive days every 4–6 weeks.